STERIS (NYSE:STE) Stock Rating Upgraded by Wall Street Zen

STERIS (NYSE:STE) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Trading Down 3.4%

NYSE:STE opened at $230.49 on Friday. The stock has a market cap of $22.60 billion, a price-to-earnings ratio of 32.15 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS has a 1 year low of $204.90 and a 1 year high of $269.44. The business has a fifty day moving average of $254.37 and a 200-day moving average of $251.55.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities analysts predict that STERIS will post 9.08 earnings per share for the current year.

Insider Activity

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares in the company, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.07% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of STERIS during the 3rd quarter valued at $25,000. Board of the Pension Protection Fund acquired a new position in shares of STERIS in the fourth quarter worth $25,000. Harbor Investment Advisory LLC raised its holdings in shares of STERIS by 115.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 60 shares in the last quarter. Activest Wealth Management raised its holdings in shares of STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 89 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in STERIS during the fourth quarter valued at $28,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.